Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.53 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2647094 | 0.88 | ALDH1A1 (0.55) | PTGS2ALDH1A1HPGDPDE4DSMN1; SMN2 | |
| SCHEMBL561576 | 0.82 | KDM5A (0.57) | KDM5AKDM5BALDH1A1HPGDKDM4E | |
| SCHEMBL4158040 | 0.79 | MEN1 (0.46) | KDM5APTGS2ALDH1A1KDM4ERAB9A | |
| SCHEMBL16058273 | 0.78 | KDM5A (0.53) | KDM5AKDM5BALDH1A1HPGDKDM4E | |
| SCHEMBL8196859 | 0.74 | PTGS2 (0.84) | PTGS2ALDH1A1SMN1; SMN2 | |
| SCHEMBL1058188 | 0.73 | KDM5A (0.68) | KDM5AKDM5BALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL6290508 | 0.71 | PDE4B (0.62) | ALDH1A1HPGDSMN1; SMN2KDM4ERAB9A | |
| SCHEMBL798337 | 0.71 | ALDH1A1 (0.73) | ALDH1A1HPGDPDE4DSMN1; SMN2KDM4E | |
| SCHEMBL2644551 | 0.70 | RAB9A (0.49) | ALDH1A1HPGDSMN1; SMN2RAB9AMAPT | |
| Propane SCHEMBL11482617 | 0.70 | ALDH1A1 (0.51) | KDM5AKDM5BALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176825-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176825-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | KDM5A 495/4885KDM5B 588/4885PTGS2 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.